EP3815684A1 — Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Assigned to Amarin Pharmaceuticals Ireland Ltd · Expires 2021-05-05 · 5y expired
What this patent protects
The invention concerns pharmaceutical compositions for use in a method of reducing the risk of cardiovascular death, coronary revascularization, and/or unstable angina in a subject on statin therapy having a fasting baseline triglyceride level of from 135 mg/dl to 500 mg/dl, and …
USPTO Abstract
The invention concerns pharmaceutical compositions for use in a method of reducing the risk of cardiovascular death, coronary revascularization, and/or unstable angina in a subject on statin therapy having a fasting baseline triglyceride level of from 135 mg/dl to 500 mg/dl, and either a) an established cardiovascular disease; or b) diabetes mellitus; being aged 50 or older; and fulfilling further criteria as defined in the claims; the pharmaceutical composition comprising 4g of eicosapentaenoic acid ethyl ester, administered to the subject per day; and the eicosapentaenoic acid ethyl ester comprising at least 96 wt.% of all omega-3 fatty acids in the pharmaceutical composition.
Drugs covered by this patent
- Vascepa (ICOSAPENT ETHYL) · Amarin Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.